NCT06810609View on ClinicalTrials.gov

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

April 20, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

September 30, 2030

Conditions
Lung Cancer Non-Small Cell Cancer (NSCLC)
Interventions
PROCEDURE

surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines

Surgical removal of the tumor in patients with resectable or borderline resectable NSCLC

RADIATION

Chemoradiotherapy

Chemoradiotherapy

DRUG

Immunotherapy

Immunotherapy (Durvalumab).

Trial Locations (1)

53127

RECRUITING

University Hospital Bonn, Bonn

All Listed Sponsors
lead

Eleni Gkika

OTHER